---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-328759"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:26:06.345229+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma CLO George Lloyd to step down; Arthur McGivern to assume role Jan 1, 2026

## Summary
- George W. Lloyd transitions from EVP and Chief Legal Officer effective Dec 31, 2025.
- Lloyd will remain employed as a senior advisor to the Company.
- Arthur R. McGivern, EVP and General Counsel, assumes CLO responsibilities on Jan 1, 2026.
- McGivern joined Royalty Pharma in Oct 2022 from Goodwin Procter LLP.

## SEC filing metadata
- accession: 0001193125-25-328759
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525328759/0001193125-25-328759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525328759/d938129d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-328759
- JSON: https://secwatch.observer/filing/0001193125-25-328759.json
- Plain text: https://secwatch.observer/filing/0001193125-25-328759.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.